| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1667 | Dansyl-neca | Potent and selective fluorescent adenosine A1 receptor agonist |
|
| DCC1668 | Dapl-in-1 | Novel inhibitor of L,L-diaminopimelate aminotransferase (DapL) |
|
| DCC1669 | Dapoxetine | Potent Selective serotonin reuptake inhibitor (SSRI) |
|
| DCC1670 | Darapladib-impurity | An impurity formed in Darapladib production |
|
| DCC1671 | Das-6-2-2-6-crbn | Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL |
|
| DCC1672 | Das-6-2-2-6-vhl | Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL |
|
| DCC1673 | Das-iap | Novel PROTAC targeting drug-resistant BCR-ABL |
|
| DCC1674 | Dasiglucagon | Novel glucagon analog for diabetic hypoglycemia therapy |
|
| DCC1675 | Dasolampanel Etibutil | Novel selective ionotropic glutamate receptor 5 (iGluR5) antagonist |
|
| DCC1676 | Daw-22 | Biological Active Reagents |
|
| DCC1677 | Db07107 | Novel tyrosine kinase inhibitor for drug resistant T315I mutant BCR-ABL |
|
| DCC1678 | Db1255 | Novel ERG/DNA binding inhibitor, targeting the DNA-binding activity of the human ERG transcription factor |
|
| DCC1679 | Db1960 | Novel antileishmanial agent, against both intracellular Leishmania donovani and intracellular Leishmania amazonensis and displaying dose-dependent reduction of liver parasitemia |
|
| DCC1680 | Dbco-stco | Novel protein cross-linking agent |
|
| DCC1681 | Dbm-1285 Dihydrochloride | p38 MAPK inhibitor, supressing p38 phosphorylation and LPS-induced TNF-α production in macrophages |
|
| DCC1682 | Dbpr110 | Potent HCV NS5A inhibitor |
|
| DCC1683 | Dc_501 | Novel selective non-nucleoside inhibitor of DNA methyltransferase 1 (DNMT1) |
|
| DCC1684 | Dc_m5_2 | Novel inhibitor of WDR5-MLL1 interaction |
|
| DCC1685 | Dc_ym21 Maleate | Novel inhibitor of menin-MLL interaction |
|
| DCC1686 | Dc_ym25 | Novel inhibitor of menin-MLL interaction |
|
| DCC1687 | Dc_ym26 | Novel inhibitor of menin-MLL interaction |
|
| DCC1688 | Dcat Maleate [57915-90-9] | Inhibitor of N-methyl transferases (NMT), preventing the formation of Parkinson's syndrome neurotoxins via methylation of non-methylated pre-neurotoxins. |
|
| DCC1689 | Dc-bpi-11 | Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets, significantly inhibiting leukemia cell proliferation |
|
| DCC1690 | Dc-bpi-7 | Novel potent BPTF-BRD inhibitor, showing selectivities 100-fold higher than those of other BRD targets |
|
| DCC1691 | Dc-cpin734 | Novel potent CBP bromodomain inhibitor with a TR-FRET IC50 value of 19.5 ± 1.1 nM and over 400-fold of selectivity against BRD4 bromodomains |
|
| DCC1692 | Dce_254 | Novel potent EZH2 inhibitor |
|
| DCC1693 | Dce_42 | Novel potent EZH2 inhibitor |
|
| DCC1694 | Dc-ebio | Activator of IK and SK channels |
|
| DCC1695 | Dcg066 | Novel inhibitor of lysine methyltransferase G9a |
|
| DCC1696 | dcg-iv | Highly potent agonist for group II mGlu receptors |
|
